Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107673
Title:
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
Authors:
Dazzi, H; Hasleton, Philip S; Thatcher, Nick; Wilkes, S; Swindell, Ric; Chatterjee, A K
Abstract:
The expression of epidermal growth factor receptor (EGF-R) in 34 formalin fixed paraffin embedded specimens of malignant mesothelioma was examined using the F4 antibody. Eight samples of reactive pleura showed homogenous cytoplasmic staining with the antibody. EGF-R positive cells (greater than or equal to 5%) were found in 68% of the mesotheliomas examined. EGF-R positivity was more commonly seen in the epithelial histological subtype than in the sarcomatous or mixed subtypes. Patients with less than 5% of mesothelioma cells staining positive for EGF-R had a significantly shorter survival (median 299 days) compared with patients whose tumours had a greater number of cells positive for EGF-R (median 446 days) (P = 0.04). However, when the histological subgroup was also taken into consideration (epithelial type had a significantly longer survival than the sarcomatous or mixed) the survival difference in relation to EGF-R positivity was no longer significant (P = 0.08). EGF-R could not be used to distinguish between malignant and benign mesothelial tissue and was not an independent prognostic factor for survival.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.
Citation:
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. 1990, 61 (6):924-6 Br J Cancer
Journal:
British Journal of Cancer
Issue Date:
Jun-1990
URI:
http://hdl.handle.net/10541/107673
PubMed ID:
2372497
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDazzi, Hen
dc.contributor.authorHasleton, Philip Sen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorWilkes, Sen
dc.contributor.authorSwindell, Ricen
dc.contributor.authorChatterjee, A Ken
dc.date.accessioned2010-07-14T16:34:35Z-
dc.date.available2010-07-14T16:34:35Z-
dc.date.issued1990-06-
dc.identifier.citationMalignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. 1990, 61 (6):924-6 Br J Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid2372497-
dc.identifier.urihttp://hdl.handle.net/10541/107673-
dc.description.abstractThe expression of epidermal growth factor receptor (EGF-R) in 34 formalin fixed paraffin embedded specimens of malignant mesothelioma was examined using the F4 antibody. Eight samples of reactive pleura showed homogenous cytoplasmic staining with the antibody. EGF-R positive cells (greater than or equal to 5%) were found in 68% of the mesotheliomas examined. EGF-R positivity was more commonly seen in the epithelial histological subtype than in the sarcomatous or mixed subtypes. Patients with less than 5% of mesothelioma cells staining positive for EGF-R had a significantly shorter survival (median 299 days) compared with patients whose tumours had a greater number of cells positive for EGF-R (median 446 days) (P = 0.04). However, when the histological subgroup was also taken into consideration (epithelial type had a significantly longer survival than the sarcomatous or mixed) the survival difference in relation to EGF-R positivity was no longer significant (P = 0.08). EGF-R could not be used to distinguish between malignant and benign mesothelial tissue and was not an independent prognostic factor for survival.en
dc.language.isoenen
dc.subjectPleural Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMesothelioma-
dc.subject.meshMiddle Aged-
dc.subject.meshPleural Neoplasms-
dc.subject.meshPrognosis-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.titleMalignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.